Release Date: November 12, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: With the largest customer indicating a decrease in orders for 2025, can some of that be made up from more orders for at-home dialysis concentrate? Where else are you looking to diversify within your core customer base? A: Yes, the at-home dialysis market is expanding, and we are working with providers in that area. The convenience pack we've introduced is significant for at-home patients. We are also expanding our relationship with the largest dialysis provider globally and looking to add more profitable products to our portfolio. Despite the anticipated revenue decline, we expect to remain profitable on an adjusted EBITDA basis.
Q: What will be the impact on EBITDA due to the revenue decline from the largest customer? Are there any costs you can reduce temporarily? A: We expect gross margin percentage to continue increasing into 2025. We are working on finalizing the EBITDA impact but anticipate remaining profitable. We will provide 2025 guidance at the beginning of the year, indicating our profitability expectations.
Q: How is the Western expansion progressing, and when do you expect to fully deploy in that territory? A: We are increasing our customer base in the West and are in discussions for a permanent position there. We hope to provide more details in the coming weeks.
Q: Are there any value-driving developments in ex-US territories planned for 2025? A: We have extended our relationship with Nipro Medical to enhance our international market presence. We are also bidding on multiple international contracts and expect to announce more developments soon.
Q: Can you provide more details on the strategic priorities and capital structure changes you mentioned? A: We are focusing on growing revenue-generating business, driving profitability, and achieving profitability in 2024. We are also managing cash, reducing debt, and placing Rockwell Medical on a stronger financial footing to rebuild shareholder value.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.